Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Proactive Investors

09:52 EST 21st January 2018 | BioPortfolio

Here are the most relevant search results for "Proactive Investors" found in our extensive news archives from over 250 global news sources.

More Information about Proactive Investors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Proactive Investors for you to read. Along with our medical data and news we also list Proactive Investors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Proactive Investors Companies for you to search.

Showing News Articles 1–25 of 599 from Proactive Investors

Friday 19th January 2018

AstraZeneca gets approval for two cancer and asthma treatments in Japan

Lynparza has been approved for use as a maintenance therapy in ovarian cancer patients, while Fasenra has been cleared as an add-on treatment for severe asthma sufferers

AstraZeneca gets approval for two cancer and asthmas treatments in Japan

Lynparza has been approved for use as a maintenance therapy in ovarian cancer patients, while Fasenra has been cleared as an add-on treatment for severe asthma sufferers

Thursday 18th January 2018

Genedrive shifts into higher gear as hepatitis C test enters new markets

Regulatory sign-off fires starting pistol on the commercial launch in Europe, Africa, EU Medical Devices Directive awarded CE IVD certification, molecular diagnostics, Europe, Africa, Sysmex

ImmuPharma confident of topline results from Phase III Lupuzor trial this quarter

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), tells Proactive the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, their lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. He adds that 200 patients have now been successfully recruited and dosed, with top line ...

Genedrive's Hepatitis C test is quick, effective and simple to use, say analysts

The diagnosis of Hepatitis C is a multi-million-dollar market opportunity

Avacta boss praises “strong” progress made in first half

“We have continued to grow the number and extent of the data packages demonstrating the power of the Affimer technology in therapeutic and non-therapeutic applications which build the commercial case and de-risk the technology for third parties”

ImmuPharma completes phase III Lupuzor study; on track to publish top-line data this quarter

The last of the 200 patients has had their final assessment and the data is now being processed and analysed

ImmuPharma completes phase III Lupuzor study; on track to publish top-line date this quarter

The last of the 200 patients has had their final assessment and the data is now being processed and analysed

Wednesday 17th January 2018

Clinigen expecting good growth from all three operations in second half

Clinigen Group PLC (LON:CLIN) chief executive Shaun Chilton discusses the group's half year trading update with Proactive's Andrew Scott. Chilton says they're well positioned for another year of growth with trading at the halfway stage in line with expectations. Revenues were up 28% year-on-year, although the figure was distorted by what are called ‘pass through costs’ associated with th...

Haydale Graphene signs supply agreement for its anti-counterfeiting technology

Ray Gibbs, chief executive of Haydale Graphene Industries PLC (LON:HAYD), tells Proactive they've entered into a commercial supply and development agreement with Australia-listed Talga Resources. The tie-up will see the two work together to produce, market and sell jointly-developed transparent conductive ink products using graphene for industrial applications in Asia. The two companies – ...

Barclays cites progress in HIV and new shingles vaccine as it turns bullish on GSK

Analyst Emmanuel Papadakis has upgraded GSK to ‘overweight’ and hiked his price target to £16.50, claiming that any risks are now priced in, while progress has been made in HIV and shingles

OptiBiotix to showcase industry-leading technology at top conference next month

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics

Haydale takes next step in commercialisation of its anti-counterfeiting technology

Haydale is looking to improve its graphene-based, transparent ink which can be ‘read’ by specially-developed software codes to verify a product’s authenticity

Genedrive making “good progress” as it hurtles towards commercialisation of its hep C test

It was a busy second half of 2017 for Genedrive, which managed to secure a CE mark of its HCV ID Kit, bring on board a distribution partner and launch the test in Africa

Clinigen Group positioned for another year of growth with trading in line at the halfway stage

We have delivered good growth and made strong progress against our strategic priorities, said chief executive Shaun Chilton

Tuesday 16th January 2018

Tissue Regenix rings changes after Cellright acquisition

Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln

ValiRx releases more positive data from VAL401 phase II lung cancer trial

The latest data from the trial shows that VAL401 had a positive impact on patients’ quality of life and doesn’t cause immune suppression like chemotherapy, for example

NetScientific hails progress of its portfolio companies in 2017

We are encouraged by the first commercial sales of Vortex's VTX-1 Liquid Biopsy System and the continued expansion of ProAxsis' assay portfolio,” said Francois Martelet, the chief executive officer of NetScientific.

Motif Bio hails Cystic Fibrosis Foundation grant

The money will be used fund early-stage research into using its next-generation antibiotic, iclaprim, to treat sufferers of the disease

Leading professor to host webinar on ANGLE’s Parsortix system

Professor Stuart martin will host the webinar on Wednesday 17 January between 5pm and 5.50pm UK time

Greggs reports 2017 sales growth but cautious on outlook amid Brexit uncertainty

Greggs will push ahead with its expansion plan this year despite a uncertain consumer environment

Genedrive’s Hep C diagnostic device excels in African performance study

Africa is host to a wider variety of genomes than Europe so Genedrive wanted to make sure its HCV ID Kit still worked well

Midatech gets US green light to begin trials on a drug that may offer hope to suffers of fatal childhood cancer

The study will be conducted at the University of Southern California, San Francisco, and the Memorial Sloan Kettering Cancer Center in New York

Monday 15th January 2018

Numis reckons Just Eat users won’t switch off because of new 50p service charge

The City broker reckons the new charge, coupled with the acquisition of Hungryhouse, will boost annual revenues by around £40mln a year

Johnson Matthey boosted by Berenberg upgrade to ‘buy’, thinks battery opportunity in "for free”

Berenberg's analysts said Johnson Matthey’s “recently announced share gains in European autocatalysts should facilitate a return to high-single-digit earnings growth, and we believe it is more than credible in batteries”


Quick Search
Advertisement

 

News Quicklinks